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choice for sleepiness in patients with obstructive sleep apnea (OSA), however, adherence is often thought
to be suboptimal. We investigated the effects of suboptimal CPAP-usage on objective and subjective
sleepiness parameters in patients with OSA. MATERIAL AND METHODS: In this 2-week, parallel,
double-blind, randomised controlled trial we enrolled moderate-to-severe OSA patients with excessive
pre-treatment daytime sleepiness (Epworth-Sleepiness-Scale [ESS] score >10 points) who had suboptimal
CPAP adherence over at least 12 months (mean nightly usage time 3-4 h). Patients were allocated through
minimisation to either subtherapeutic CPAP (”sham-CPAP”) or continuation of CPAP (therapeutic-
CPAP). A Bayesian analysis with historical priors calculated the posterior probability of superiority.
RESULTS: Between May, 2016 and November, 2018, 57 patients (60±8 years, 79% men, 93% Caucasian)
were allocated in total, and 52 who completed the study (50% in each arm) were included in the final
analysis. The unadjusted ESS-score increase was +2.4 points (95% CI +0.6 to +4.2; p=0.01) in the
sham-CPAP-group when compared to continuing therapeutic CPAP. The probability of superiority of
therapeutic CPAP over sham CPAP was 90.4% for ESS, 90.1% for systolic, and 80.3% for diastolic
blood pressure. CONCLUSIONS: Patients with moderate-to-severe OSA and daytime sleepiness are still
getting a substantial benefit from suboptimal CPAP adherence, albeit not as much as they might get if
they adhered more. Whether a similar statement can be made for even lower adherence levels remains
to be established in future trials.
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Word count:  27 
3,262 words 28 
Take home message: 29 
Patients with obstructive sleep apnea and daytime sleepiness are still getting a 30 
substantial benefit from suboptimal CPAP adherence (i.e. 3 to 4 hours per night) 31 
albeit not as much as they might get if they adhered more.  32 
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Abstract 33 
Introduction. Continuous positive airway pressure (CPAP) is currently the treatment of choice 34 
for sleepiness in patients with obstructive sleep apnea (OSA), however, adherence is often 35 
thought to be suboptimal. We investigated the effects of suboptimal CPAP-usage on objective 36 
and subjective sleepiness parameters in patients with OSA. 37 
Material and Methods. In this 2-week, parallel, double-blind, randomized controlled trial we 38 
enrolled moderate-to-severe OSA patients with excessive pre-treatment daytime sleepiness 39 
(Epworth-Sleepiness-Scale [ESS] score >10 points) who had suboptimal CPAP adherence over 40 
at least 12 months (mean nightly usage time 3-4 hours). Patients were allocated through 41 
minimization to either subtherapeutic CPAP (“sham-CPAP”) or continuation of CPAP 42 
(therapeutic-CPAP). A Bayesian analysis with historical priors calculated the posterior 43 
probability of superiority. 44 
Results. Between May, 2016 and November, 2018, 57 patients (60±8 years, 79% men, 93% 45 
Caucasian) were allocated in total, and 52 who completed the study (50% in each arm) were 46 
included in the final analysis. The unadjusted ESS-score increase was +2.4 points (95% CI +0.6 47 
to +4.2; p=0.01) in the sham-CPAP-group when compared to continuing therapeutic CPAP. 48 
The probability of superiority of therapeutic CPAP over sham CPAP was 90.4% for ESS, 90.1% 49 
for systolic, and 80.3% for diastolic blood pressure. 50 
Conclusions. Patients with moderate-to-severe OSA and daytime sleepiness are still getting a 51 
substantial benefit from suboptimal CPAP adherence, albeit not as much as they might get if 52 
they adhered more. Whether a similar statement can be made for even lower adherence levels 53 
remains to be established in future trials. 54 
Keywords: obstructive sleep apnea; suboptimal; continuous positive airway pressure; 55 
randomized controlled trial  56 
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Introduction 57 
Symptomatic obstructive sleep apnea (OSA) affects 1–2% of females and 2–4% of males in the 58 
general population, while the prevalence of asymptomatic OSA is considerably higher.[1, 2] 59 
Untreated patients with OSA are at increased risk for all-cause and cardiovascular mortality, 60 
adverse medical outcomes, and poor neurocognitive performance.[3] Patients with OSA 61 
typically complain about non-restorative sleep, fatigue, insomnia and excessive daytime 62 
sleepiness. The latter finds its most commonly mentioned reflection in vehicle crashes being 63 
two to three times more common among patients with untreated OSA than in the general 64 
population.[4]  65 
Population-based studies have demonstrated a directly proportional relationship between the 66 
severity of OSA and healthcare costs.[5] Excessive daytime sleepiness is arbitrarily defined as 67 
an Epworth Sleepiness Scale [ESS] score >10 and applies to 23% of the general population.[6] 68 
A score >10 seems to independently increase health care utilization.[7] Considering indirect 69 
costs of untreated OSA (e.g. due to lost productivity and  illness-related accidents), its overall 70 
economic burden is likely to be far greater.[8] 71 
According to current guidelines, the treatment of choice for OSA is continuous positive airway 72 
pressure (CPAP) therapy.[9] Data from randomized controlled trials (RCTs) have consistently 73 
shown that CPAP improves sleepiness, reduces the risk of comorbidities (e.g. high blood 74 
pressure (BP)) and improves quality of life (QoL).[10-12] However, its overall effectiveness 75 
seems to broadly correlate with the average nightly usage time[11], although there is no 76 
consensus on the definition of “non-adherence.” A commonly held view is that a patient should 77 
use their CPAP device for at least 4 hours per night to experience an improvement of sleepiness 78 
and daily functioning.[13-18] However, a considerable proportion of CPAP users fail to achieve 79 
this threshold. Accordingly, 46-83% of the patients on CPAP could be described as 80 
insufficiently treated, if optimal adherence were defined as >4 hours of nightly use.[19]  81 
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In contrast to the findings from observational data, indirect evidence from interventional trials 82 
does not support an apparent threshold of mean usage time necessary to reduce sleepiness in 83 
OSA. A recent meta-analysis could not find a dose-dependent response of ESS to CPAP 84 
adherence, which suggests that a broad spectrum of therapy usage time is beneficial for this 85 
outcome.[10] This is in opposition to what is known from studies on comorbidities, e.g. on high 86 
BP, where a dose-dependent reduction could be demonstrated.[11] Thus it remains unclear, if 87 
and how much suboptimally treated patients actually benefit from CPAP, or whether the 88 
treatment could be withdrawn altogether without any health-related consequences. 89 
Additionally, in some countries, reimbursement rules for CPAP devices depend on their average 90 
usage time (e.g. a threshold at 4 hours per night), however, interventional data is lacking. 91 
In this study, we aimed to evaluate moderate-to-severe OSA patients with documented mean 92 
CPAP usage times between 3 and 4 hours per night for effects of therapy withdrawal on 93 
sleepiness. We hypothesized that two-weeks of CPAP withdrawal would result in the return of 94 
OSA and its sequelae despite apparent prior suboptimal use.  95 
Methods 96 
Trial design. This two-week, parallel, double-blind RCT investigated the effects of suboptimal 97 
continuous positive airway pressure (CPAP) treatment on subjective sleepiness and other 98 
parameters in patients with obstructive sleep apnea (OSA). We applied the previously described 99 
CPAP-withdrawal model[20, 21], where either a therapeutic or a sham-CPAP device is 100 
assigned. While identical in appearance, noise production, and operability, the sham CPAP 101 
device is not able to deliver a therapeutic pressure. This is achieved by 1) a built-in flow-102 
restrictor; 2) altered software settings; and 3) a leakage at the mask-end of the tubing intended 103 
to prevent rebreathing of CO2. This design allows double-blinding and placebo effect without 104 
lessening the severity of OSA or improving the architecture of sleep.[22, 23] 105 
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Study population. To be included in our RCT, patients had to: 1) have a sleep-lab confirmed 106 
diagnosis of OSA with a 4%-Oxygen-Desaturation-Index (ODI4%) of at least 15/h and an 107 
Epworth Sleepiness Scale (ESS) score >10 points - both prior to commencing the CPAP 108 
therapy; 2) have been treated with CPAP for at least 12 months prior to inclusion in our study 109 
- as protocolled by the 1-year-statistics of the device showing a residual Apnoea-Hypopnea-110 
Index (AHI) < 10/h and a mean usage time between three and four hours per night; 3) show at 111 
least a one-time re-emergence of ODI4% ≥15/h during a four-night CPAP-withdrawal - as 112 
measured by ambulatory night-time pulse oximetry. The exclusion criteria were: 1) previously 113 
registered ventilatory failure (awake PaO2 <9 kPa or arterial PaCO2 >6 kPa); 2) unstable and/or 114 
untreated coronary or peripheral artery disease; 3) severe uncontrolled arterial hypertension 115 
(mean BP values >180/110mmHg in serial measurements); 4) previously diagnosed Cheyne-116 
Stokes breathing pattern; 5) current professional driving; 6) age of <20  or >75 years at trial 117 
entry; 7) pregnancy. The trial was pre-registered at ClinicalTrials.gov (NCT02781740). All 118 
tests were conducted by the University Hospital Zurich and approved by the cantonal ethics 119 
committee of Zurich (KEK-ZH-Nr. 2016-00332). All patients provided written informed 120 
consent according to the Declaration of Helsinki. Data were obtained according to Good 121 
Clinical Practice (GCP) guidelines. 122 
Procedures. Visits with clinical assessments were performed at 1) inclusion; 2) baseline 123 
inpatient respiratory polygraphy (RP) upon outpatient confirmation of persistence of relevant 124 
OSA; 3) follow-up inpatient RP after 2 weeks of intervention. A detailed description of the 125 
procedures can be found in the online supplement. The RPs were evaluated according to the 126 
Guidelines by the American Association of Sleep Medicine from 2007 (AASM 2007 version 127 
B).[24] Regular controls of our RCT were performed by an external monitor who was otherwise 128 
not involved in the study. 129 
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Outcomes. The primary outcome was the change in ESS after two weeks. Secondary outcomes 130 
included 1) AHI and ODI4%  - as measured by RP; 2) test duration, number of missed signals 131 
and time to first 4 subsequently missed signals (“time to S4”) – as measured by Oxford Sleep 132 
Resistance Tests (OSLER); 3) mean/average, minimal and maximal reaction time – as 133 
measured by Multiple Unprepared Reaction Time Test (MURT); 4) mean nightly CPAP usage 134 
over two weeks – as protocolled by the CPAP device; 5) systolic and diastolic BP and HR 135 
values over two weeks – as measured shortly before/after RP and protocolled in the patient 136 
diary; 6) self-assessed quality of life (QoL) – as represented by different parameters from the  137 
36-Item Short Form Health Survey (SF-36) and Functional Outcomes of Sleep Questionnaire 138 
(FOSQ-10).  139 
Statistical analysis. A sample size of 52 (26 per arm) was estimated to detect the minimal 140 
clinically important difference (MCID) with 80% power at the two-sided significance level of 141 
0.05. This calculation assumed a standard deviation of 2.5 points for the change in ESS score 142 
between baseline and follow-up (based on our previous CPAP withdrawal trial[20]). A MCID 143 
of 2 points on the ESS was chosen based on three aspects: 1) pooled RCTs have confirmed this 144 
threshold to interpret the clinical relevance of changes in ESS[25]; 2) a 2 point decrease is 145 
considered economically viable by NICE[26], and 3) such a decrease is expected to improve 146 
work productivity by 2% and reduce sleep-related road accidents by about 9%.[27]  147 
Comparison between baseline characteristics of the intervention group were performed using 148 
the Wilcoxon rank sum test with continuity correction (continuous variables) or Fisher`s exact 149 
test (categorical variables). A per protocol analysis was performed. For all outcomes, we 150 
considered a univariate linear regression analysis adjusting for treatment group and baseline 151 
measurements of the outcome. A multivariate linear regression was performed as well, a two-152 
sided significance level of <0.05 was used to determine statistical significance. 153 
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We also performed a Bayesian analysis because incorporation of historical data into current 154 
increases the probability of reproducibility.[28] Details on the Bayesian analysis including the 155 
systematic review can be found in the online supplement. The statistical analysis was performed 156 
with STATA Version 15 (StataCorp LP, College Station, TX) and R (R Core Team 2018, 157 
version 3.4.4 (2018-03-15)).  158 
Results 159 
Patient characteristics. From May 27, 2016 to November 10, 2018, 1035 patients from nine 160 
Swiss sleep laboratory centers (Kantonsspital Aarau, Kantonsspital Glarus, Kantonsspital 161 
Graubünden, Spital Horgen, Spital Männedorf, Kantonsspital Schaffhausen, Stadtspital 162 
Triemli, Universitätsspital Zürich, Zürcher RehaZentrum Wald) were identified as possibly 163 
eligible and contacted by mail. Fifty-seven patients (mean age 60.1 ± 8.0 years; 78.9% men; 164 
93% Caucasian; 7% Asian) were randomized. Five patients discontinued the study, one of them 165 
due to a hypertensive serious adverse event possibly related to the study intervention 166 
(hypertensive crisis, Figure 1). The last patient completed the study on November 10, 2018. 167 
The final analysis encompassed 26 patients assigned to the sham- and 26 to the therapeutic 168 
CPAP-arm.  169 
The trial profile can be seen in Figure 1, the baseline characteristics in Table 1. The additional 170 
information on study participants (comorbidities, medication) can be found in the online 171 
supplement. Subtherapeutic CPAP (i.e. the sham CPAP arm) was associated with re-emergence 172 
of OSA as evidenced by a significant increase in AHI from baseline (+33.4 /h [95% CI +23.3 173 
to +43.6] p<0.001). 174 
Primary outcome. In comparison to the control group, sham-CPAP led to an unadjusted 175 
increase in the ESS score by +2.4 points (95% CI +0.6 to +4.2), however a part of this effect 176 
might have been mediated by a higher than baseline CPAP-adherence in the control group. 177 
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Although both study arms had a similar CPAP adherence during the two weeks prior to 178 
randomization (sham [mean ± standard deviation]: 3.5 ± 0.6 hours, therapy: 3.1 ± 0.8 hours), 179 
the adherence dropped to 2.1 ± 1.8 hours in the sham group and rose to 4.6 ± 1.8 hours in the 180 
control group (66% of all patients in this arm had a CPAP adherence above 4 hours at follow-181 
up). The divergence in CPAP adherence was statistically significant (+1.9 hours [95% CI +0.4 182 
to +3.6] p=0.017), but adjusting for this confirmed the primary outcome to still be statistically 183 
significant (adjusted ESS score increase of +2.0 points [95% CI +0.5 to +3.2], p=0.011). 184 
Additionally, in the isolated single arm analysis (i.e. only sham CPAP) the ESS score 185 
significantly increased by means of a paired t-test (+2.1 points [95% CI +0.5 to +3.2], p=0.020). 186 
Secondary outcomes. Analogous to the ESS score, the FOSQ score worsened significantly in 187 
the sham intervention group (Table 2). Further baseline characteristics are reported in the online 188 
supplement, Table 2-3. The results of all secondary outcomes can be found in Table 2 and the 189 
online supplement, Table 4.  190 
Objective sleepiness parameters. There was no effect on both independent ways to objectively 191 
assess sleepiness (i.e. the OSLER and MURT test). A non-significant trend which corresponded 192 
to the ESS change was mostly limited by a low sample size (Table 2). 193 
Usage patterns. Twenty-eight (49%) participants reported their pre-trial suboptimal CPAP 194 
adherence was due to their lifestyle, 25 (44%) due to comorbidities, and 4 (7%) due to 195 
“technical issues.” Further information regarding the categorization and the individual reasons 196 
can be found in the online supplement, Table 5. CPAP adherence patterns did not differ between 197 
these three groups (p-value for difference [global test] = 0.523).  198 
Bayesian analysis. Based on a systematic review (Online supplement, Figure 1) historical data 199 
from four trials were included for ESS (2866 patients)[29-32], while only two provided 200 
historical data for BP (2376 patients)[29, 30]. In the current study data, we observed a difference 201 
in ESS between the treatment arms of about 2.4 points, while in the historical data there was a 202 
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mean difference of about 1.3 points. Small differences in blood pressure were also observed in 203 
the current study data (see Table 2), and in the historical data (systolic BP: sham group +1.3 204 
mmHg, therapeutic group -0.01 mmHg; diastolic BP: sham group -0.1 mmHg, therapeutic 205 
group -0.7 mmHg). Sampling from the posterior distributions, and computing the differences 206 
between the treatment arms, we obtained a median difference in delta ESS of 0.825 points 207 
(sham - therapeutic, positive favors therapeutic; 95% Credible Interval --0.41 to 2.05). The 208 
posterior probability of superiority for ESS and BP is 90.4% (Table 3).  209 
Discussion 210 
This is the first RCT to investigate explicitly pre-defined suboptimal CPAP usage and delineate 211 
individually reported reasons for lower adherence in a representative population. Our RCT 212 
demonstrated that suboptimal adherence to CPAP therapy improves subjective daytime 213 
sleepiness in patients with moderate-to-severe OSA, since withdrawal of therapeutic CPAP for 214 
two weeks resulted in a +2.4 points increase or 90.4% probability of superiority on the ESS. 215 
Large scale meta-analyses in this field have suggested that CPAP use in similar populations is 216 
associated with an even greater reduction in ESS score of 2.5 to 2.9 points.[10, 33] The effect 217 
of suboptimal CPAP-therapy on subjective daytime sleepiness was virtually the same as the 218 
one reported for usage times of four to seven hours per day.[10] However, approximately a 219 
third of our effect size might be due to improvements due to increases in CPAP adherence (see 220 
Result section). Whether similar statements can be made for lower adherence remains to be 221 
established in future trials. In other words, this trial does not foreclose a non-existing dose-222 
response effect of CPAP on subjective daytime sleepiness, the potential threshold might just be 223 
lower than 3 hours of usage time. 224 
The effect of CPAP on the ESS score in our trial (per protocol analysis +2.4 points, adjusted: 225 
+2.0 points; single arm analysis: +2.1 points) was robust and confirmed our primary hypothesis 226 
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(+2 points). Previous studies confirm that this 2-point change is not only statistically significant, 227 
but also clinically relevant.[25-27, 34] On the other hand, we were not able find objectively 228 
measurable correlates of sleepiness (i.e. significant effects for the OSLER and MURT test). 229 
Correspondingly, a previous meta-analysis indicated that the effect of CPAP on subjective 230 
sleepiness is generally larger than on objective measurements[33], which could provide partial 231 
explanation for our results. Since objective measures have always been less sensitive compared 232 
to subjective ones in this setting, one can hypothesize that objective measures (e.g. the OSLER 233 
or MURT test) do not fully characterize the symptoms of a patient. 234 
In our study, participants of both arms diverged from their previously similar mean nightly 235 
CPAP times (therapy: 3.1 ± 0.8 hours, sham: 3.5 ± 0.6 hours) towards higher values in the 236 
therapeutic (4.6 ± 1.8 hours) and lower values in the sham group (2.1 ± 1.8 hours). This yielded 237 
a significant mean difference of 1.9 hours. The substantial impact of allocation to therapy 238 
adherence has already been reported in other interventional trials by other groups involving 239 
sham CPAP devices and seems to be a universal phenomenon across sex, race, and age-240 
boundaries.[23, 35-37] In the literature, this phenomenon is also referred to as the “Hawthorne 241 
effect”, where individuals modify an aspect of their behavior in response to their awareness of 242 
being observed. Interestingly, in multivariable analyses, the treatment allocation was the 243 
strongest predictor of CPAP adherence within RCTs.[35] Possible additional explanations for 244 
this include (subconscious) dissatisfaction with the current treatment in the sham-CPAP arm, 245 
or simply unblinding.[36] Indeed, data from a meta-analysis suggests that a clinically 246 
significant proportion (approximately 30%) of the effectiveness of CPAP adherence in reducing 247 
sleepiness is probably caused by patient expectation of benefit.[38] In our study, we could rule 248 
out substantial unblinding, as only 59% of all study participants correctly guessed their 249 
allocation. This is in line with previous results by other groups using the CPAP withdrawal 250 
model, where 56% of participants could guess their true allocations correctly, which was only 251 
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slightly higher than what one could expect by chance.[23] The fact, that the single arm analysis 252 
(i.e. only sham CPAP) also showed a clinically significant effect on the ESS, is reassuring.  We 253 
suspect that the patients from the suboptimal collective might be more sensitive to any changes 254 
in their therapy regimens – for example on account of lifestyle circumstances and comorbidities 255 
having been classified as more than 90% of the reasons reported behind their generally lower 256 
adherence (Online supplement, Table 5). Considering other potential benefits of longer nightly 257 
CPAP usage (e.g. lower arterial blood pressure[11]), future trials should investigate different, 258 
focused ways of boosting adherence that might be efficiently incorporated in the clinical setting.  259 
Although previous studies did not show a dose-dependent reaction of many objective surrogates 260 
of daytime sleepiness (e.g. maintenance of wakefulness test) to CPAP adherence, they were 261 
able to detect significant drops in proportions of patients with normalized or significantly 262 
improved ESS-, FOSQ- and SF-36 scores when CPAP was used less than four hours per night. 263 
[13, 15],[17, 18]  Already compliant patients were also demonstrated to increase their mean 264 
usage times and relevant scores even further upon additional, intensive support.[39] These 265 
notions most probably led to the widely recommended threshold of 4 hours of mean usage time 266 
of CPAP therapy to be considered sufficient. Still, the meta-analysis comparing treatment 267 
effects of CPAP vs mandibular advancement devices, encompassing 67 studies, noted no 268 
evidence of studies reporting higher CPAP adherence also reporting larger treatment effects 269 
(p=0.7).[10]  270 
In lieu of our findings and pre-existing literature, the widely used four-hour-threshold for 271 
clinical benefit seems unjustified. We could think of several additional reasons to support that 272 
claim: 1) Sleep and sleepiness feature a great interpersonal variability, and a one-size-fits-all 273 
approach may not be adequate. 2) There seems to be a substantial subgroup of patients with 274 
OSA who, although sleeping for more than five hours per day, deliberately keep their CPAP 275 
intervals on levels which might be regarded as “suboptimal” (i.e. <4 hours per day) over a long 276 
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period of time. When asked about their motivation, these patients often report being satisfactory 277 
treated at “their personal level.” 3) Sleep itself is not uniform in its function and does exhibit a 278 
substantial variation in terms of restorability. CPAP therapy might therefore indeed have a 279 
lower time-threshold for countering excessive sleepiness, which would not necessarily be 280 
applicable to countering other sequelae of OSA (e.g. high BP). Apart from the possibility of the 281 
overall time-thresholds for countering sleepiness and other sequelae being different, it is also 282 
conceivable that other aspects play their roles as well. The thresholds of CPAP efficacy on 283 
different sequelae of OSA may not only be individual, but also composite – e.g. involving 284 
patterns of usage, adaptive pressures or varying air compositions.     285 
The current trial population only consisted of a selected group of patients with excessive 286 
daytime sleepiness and moderate-to-severe OSA, thus the conclusions might not be 287 
generalizable to other populations with OSA. Another limitation of the current trial is the 288 
relatively short withdrawal period of two weeks, which might not feature the full effect of CPAP 289 
on daytime sleepiness. However, the ESS was primarily designed for a two week period and 290 
the test-retest reliability in this timeframe is sufficiently high.[40] Finally, the ESS score itself 291 
is prone to subjectivity and does represent an ordinal variable (and not an interval scale), thus 292 
conclusions regarding the effect size might be distorted.[41] Additionally, potential unblinding 293 
might have contributed to CPAP adherence during the trial and thus affected the outcome.  294 
Nevertheless, the ESS score was chosen as the primary outcome, as it is the most widely used 295 
clinical instrument for evaluating sleepiness and most investigated marker for subjective 296 
daytime sleepiness. 297 
We conclude, that patients with daytime sleepiness are still getting a substantial benefit from 298 
suboptimal CPAP adherence albeit not as much as they might get if they adhered more. 299 
Therefore, suboptimal CPAP usage between 3 and 4 hours/night in moderate-to-severe patients 300 
with OSA might not be a valid reason to stop treatment or not reimburse treatment at all. 301 
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Whether a similar statement can be made lower adherence and/or very severe OSA remains to 302 
be established in future trials. Therefore, future trials should consider a larger spectrum of 303 
CPAP usage patterns (different mean usage times and their intervalled distributions) in a variety 304 
of OSA patients. Attention should be drawn to investigating different, focused ways of boosting 305 
adherence that might be efficiently incorporated in the clinical setting.   306 
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Tables 446 









Age, years 61.5 ± 6.5 60.1 ± 8.7 
Sex, male  21 (81%) 21 (81%) 
BMI, kg/m2 32.2 ± 4.4 33.0 ± 4.9 
Height, cm 172.1 ± 9.7 174.6 ± 7.5 
Weight, kg 95.6 ± 16.0 100.1 ± 13.3 
Neck circumference, cm 42.2 ± 3.6 43.5 ± 3.5 
Waist circumference, cm 113 ± 14 115 ± 14 
Hip circumference, cm 108 ± 11 108 ± 11 
Mallampati score, class 2.7 ± 1.0 2.4 ± 1.0 
CPAP adherence data 
CPAP adherence (over 365 days), hr/day* 3.5 ± 0.4 3.3 ± 0.4 
Leakage (over 365 days), l/min* 1 (0 to 6) 0 (0 to 2.5) 
Obstructive sleep apnea  
Time since diagnosis of OSA, years 5.4 ± 3.3 5.4 ± 3.2 
Apnea-hypopnea index at diagnosis, hr-1 46.7 ± 21.8 38.8 ± 17.9 
Apnea-hypopnea index during CPAP, hr-1* 3.3 ± 2.5 2.2 ± 2.5 
Epworth Sleepiness Scale at diagnosis, points 12.3 ± 2.6 12.1 ± 2.4 
Epworth Sleepiness Scale at study inclusion, points** 8.5 ± 3.9 9.5 ± 4.7 
Apnea-hypopnea index during CPAP, hr-1* 3.3 ± 2.5 2.2 ± 2.5 
Data are n (%), median (interquartile range), or mean ± SD as appropriate. BMI, body mass index; 448 
OSA, obstructive sleep apnea. * data downloaded from CPAP device ** before pulse oximetry449 
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Table 2. Per protocol analysis on primary and secondary outcomes. 
 
Subtherapeutic CPAP (sham) 
n=26 
Therapeutic CPAP (real) 
n=26 
Treatment effect 
 Baseline Follow-up Baseline Follow-up Change* 95% CI p-value 
Trial outcomes 
Epworth Sleepiness Scale, points 8.3 ± 4.8 10.3 ± 5.6 8.7 ± 4.0 8.2 ± 3.7 +2.4 +0.6 to +4.2 0.010 
OSLER: time to 4 missed signals, minutes 7 (4 to 19) 18 (3 to 23) 7 (2 to 24) 6 (2 to 39) +8 -12 to +28 0.435 
OSLER: total signals missed 7 (4 to 19) 17.5 (18 to 33) 7 (2 to 24) 6 (2 to 39) +17 -15 to +49 0.289 
MURT: mean reaction time, milliseconds 268 ± 54  300 ± 73 312 ± 87 318 ± 101 +21 -21 to +65 0.317 
Systolic blood pressure (office), mmHg 132.8 ± 14.7 132.5 ± 15.6 133.6 ± 16.4 129.3 ± 14.7 +2.9 -3.8 to +9.6 0.384 
Diastolic blood pressure (office), mmHg 82.3 ± 8.3 84.3 ± 11.6 83.5 ± 11.2 82.2 ± 10.6 +2.4 -3.1 to +7.9 0.388 
Quality of life (SF-36 standardized scores) 
FOSQ, points 17.9 ± 1.9 17.9 ± 2.0 17.8 ± 2.9 17.0 ± 2.0 +1.1 0.1 to +2.4 0.044 
Physical Role  66 ± 39 59 ± 41 63 ± 39 62 ± 39 -9 +5 to -24 0.223 
Physical Functioning  76 ± 22 72 ± 25 72 ± 28 72 ± 26 -3 -11 to +5 0.445 
Emotional Role  65 ± 41 63 ± 42 71 ± 41 77 ± 31 -10 -25 to +5 0.173 
Social Functioning  74 ± 25 78 ± 26 77 ± 24 77 ± 22 +4 -3 to +12 0.242 
Vitality  51 ± 19 47 ± 21 55 ± 18 54 ± 21 -2 -5 to +9 0.544 
Bolidy Pain  68 ± 28 68 ± 25 60 ± 31 58 ± 32 -2 -11 to +6 0.575 
Mental Health 68 ± 20 68 ± 20 74 ± 20 73 ±19 0 -6 to +6 0.985 
General Health  66 ± 23 60 ± 20 58 ± 20 61 ± 18 -6 -12 to +1 0.094 
Health Transition  40 ± 24 47 ± 25 47 ± 25 48 ± 21 +3 -7 to 13 0.614 
Sleep variables 
Apnea-Hypopnea Index, hr-1 4.9 (2.5 to 10.9) 34.3 (23.1 to 51.7) 4.1 (2.5 to 7.1) 3.6 (2.2 to 5.7) +33.4 +23.3 to +43.6 <0.001 
Oxygen-Desaturation Index 4%, hr-1 4.9 (2.5 to 9.9) 35.1 (17.5 to 61.6) 4.0 (2.5 to 7.1) 4.0 (1.9 to 6.8) +33.1 +21.7 to +44.4 <0.001 
Sleep time, hours 6.2 (5.5 to 7.2) 6.3 (5.3 – 7.5) 6.4 (5.4 – 7.8) 6.5 (5.4 to 7.6) +0.1 -10.1 to +19.5 0.445 
Data are in mean ± standard deviation (mean±SD) or median (IQR). FOSQ= Functional Outcomes of Sleep Questionnaire 10; MURT= Multiple Unprepared 
Reaction Time Test; OSLER= Oxford Sleep Resistance Test; SF36= Short Form 36 Questionnaire. 
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* adjusted for baseline. In in the isolated single arm analysis the primary outcome significantly increased by +2.2 points ([95% CI +0.7 to +3.8], p=0.005) in the 
sham CPAP arm.
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Table 3. Primary and secondary endpoint Bayesian analysis using historical data from four RCTs[29-32] with a CPAP adherence between 3 and 4 hours. A 
























Epworth Sleepiness Scale 52 + 2866 -0.4128 0.8248 2.051 0.0009 90.41 % 
Systolic blood pressure 52 + 2376 -0.8241 1.6045 4.043 0.0009 90.17 % 
Diastolic blood pressure 52 + 2376 -1.0352 0.8044 2.662 0.0013 80.27 % 
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Figures 





* one patient was unblinded and consequently withdrawn from the trial due to a hypertensive urgency. 




Seite 23 von 39 
 
ONLINE SUPPLEMENT 
Effects of suboptimal adherence of CPAP-therapy on symptoms of 
obstructive sleep apnea: a randomized, double-blind, controlled trial. 
Thomas Gaisl, MD1; Rejmer Protazy1; Sira Thiel1; Sarah R. Haile, PhD2; Martin Osswald1, 
Malgorzata Roos, PhD2; Prof Konrad Bloch1; Prof John R. Stradling3; Prof Malcolm Kohler1,4 
1 Department of Pulmonology, University Hospital Zurich, Zurich, Switzerland 
2 Epidemiology, Biostatistics, and Prevention Institute, University of Zurich, Zurich, Switzerland 
3 National Institute for Health Research (NIHR) Oxford Biomedical Research Centre based at 
Oxford University Hospitals NHS Foundation Trust and University of Oxford, Oxford, United 
Kingdom  
4 Centre for Interdisciplinary Sleep Research, University of Zurich, Zurich, Switzerland 
 
Methods ................................................................................................................................................. 24 
Screening ........................................................................................................................................... 24 
Confirmation of relevant OSA ............................................................................................................ 24 
Respiratory polygraphies (RPs) ......................................................................................................... 24 
CPAP device ...................................................................................................................................... 25 
Patient diaries .................................................................................................................................... 25 
Vigilance tests .................................................................................................................................... 25 
Sleepiness and QoL questionnaires .................................................................................................. 26 
Bayesian analysis .................................................................................................................................. 27 
Eligibility criteria of randomized controlled trials ................................................................................ 27 
Databases .......................................................................................................................................... 27 
Search terms used for MEDLINE and Cochrane library .................................................................... 27 
Figure 1. Detailed PRISMA study flow-chart ......................................................................................... 28 
Statistical methods ............................................................................................................................. 29 
Table 1. Studies for the Bayes analysis (historical data) ...................................................................... 31 
Results ................................................................................................................................................... 32 
Table 2. Comorbidities of patients included in the final analysis. .......................................................... 32 
Table 3. Medication of patients included in the final analysis. .............................................................. 33 
Table 4. Blood pressure profiles by study arms. ................................................................................... 33 
Table 5. Suboptimal CPAP-adherence profiles of all study participants. .............................................. 34 
References ............................................................................................................................................ 35 
 
 




Patients were screened at the following institutions: 1) University Hospital Zurich (internal 
search performed by us); 2) Independent association of “Lunge Zürich” (who, on our behalf, 
provided a pre-selection of potential participants derived from their data base after written 
permissions from the following referring hospitals had been obtained: Spital Männedorf, 
Zürcher RehaZentrum Wald, Spital Triemli and Spital Horgen); 4) Kantonsspital Aarau, 
Kantonsspital Graubünden, Kantonsspital Schaffhausen, Kantonsspital Münsterlingen and 
“Lunge Glarus” (external search performed by us after written permissions had been obtained 
within the scope of trans-regional collaborations).   
Confirmation of relevant OSA 
The patients had to wear wrist pulse oximeters (Pulsox-300i, Konica Minolta Sensing Inc., 
Osaka, Japan) at home during each night of the four-night period off CPAP. Regular CPAP 
therapies had to be resumed for at least two weeks prior to minimization/allocation.  
Randomization and masking. The MS-DOS program MINIM (London, UK) was used to 
allocate participants by two minimization criteria: maximal off-CPAP ODI4% </> 30/h (from 
four consecutive CPAP withdrawal nights) and body mass index (BMI) </> 30 kg/m2. After 
random allocation, every participant received the same model of CPAP-machine. Each device 
was marked with a random 5-digit code (generated via random.com) masking the allocation for 
patients and investigators throughout the whole trial. Regular controls of our RCT were 
performed by an external monitor who was otherwise not involved in the study. 
Respiratory polygraphies (RPs) 
Baseline inpatient RPs were performed under therapeutic CPAP in both arms. Follow-up RPs 
were performed after two weeks under either therapeutic (control arm) or subtherapeutic CPAP 
(intervention arm) settings. Inpatient RPs were recorded by Alice 6 Diagnostic System (Philips 
Respironics, PA, USA), scored with validated Somnolzyer 24x7 software (Philips Respironics, 
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PA, USA)1 and reviewed manually. The recommendations of the American Academy of Sleep 
Medicine from 2007 were applied (AASM 2007 Version B)2 with quantification of OSA-
severity by AHI and ODI4%.  
CPAP device 
For this trial we used AirSense AutoSet S10 by ResMed (San Diego, CA, USA). All patients 
were trained to operate the study CPAP-device and explicitly advised to continue their usual 
CPAP routines. Participants, as well as outcome assessors, remained blinded to the arm-
assignment until completion of the data analysis. 
Patient diaries 
During the two weeks of intervention, the patients had to keep a diary to record their systolic 
and diastolic blood pressure (BP) and heart rate (HR) values three times a day (morning, 
midday, evening) with three subsequent measurements at a time, as well as note special 
occurrences (if any). For measuring BP and HR, each participant was provided with the same, 
clinically validated device (OMR-M7-IT, HEM-7322T, Omron, Advance AG, Switzerland) 
and trained in its use. 
Vigilance tests 
Immediately after each RP (at baseline and on the follow-up visit) a one-time Oxford Sleep 
Latency Test (OSLER) and a one-time Multiple Unprepared Reaction Time (MURT) test were 
performed. The clinical circumstances of those tests were controlled to ensure low external 
stimulation: 1) Performance in the same, darkened room with sound insulation and observation 
via infra-red camera; 2) Confiscation of cell phones, smart devices and watches prior to testing; 
3) Testing prior to breakfast, morning medication or the habitual use of stimulants in the 
morning (e.g. tobacco, caffeine). The participants were allowed to freely change their bodily 
positions for the duration of the tests.   
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Sleepiness and QoL questionnaires 
After each RP, the participants had to fill out the same bundle of three questionnaires: the 
Epworth Sleepiness Scale (ESS), the Functional Outcomes of Sleep Questionnaire (FOSQ-10) 
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Bayesian analysis 
To supplement the classical analysis, we also considered historical data. Historical trials were 
identified via a systematic review of the literature.  
 
Eligibility criteria of randomized controlled trials 
• Aged ≥18 years 
• Diagnosis of obstructive sleep apnea (OSA) defined by an apnoea–hypopnoea index (AHI) 
≥5/h 
• Random assignment to any combination of continuous positive airway pressure (CPAP, fixed 
or autotitrating), or an inactive control (sham-CPAP, any other type of placebo [e.g. placebo 
tablet], no treatment, or usual or standard care) 
• RCTs of patients with a concurrent disease (eg, heart failure and stroke) were eligible for 
inclusion 
• Assessment of Epworth Sleepiness Scale (ESS), or Short Form (36) Health Survey (SF-36), 
or arterial blood pressure (ambulatory, office measurements) at baseline and a follow-up visit 
and reported with some measure of variability (eg, standard deviation or error) either the 
average number (i.e. points, standardized score, or mmHg) at each visit, the average change 
in each group at follow-up compared with baseline, or a treatment effect for the difference in 
the change of the number between groups 
• Parallel or crossover randomized controlled trial design 
 
Comment: If two eligible trials contained a significant overlap in patients, the larger of the two trials 
was used in the analysis. 
 
Databases 
• MEDLINE (from inception to December 1, 2018) 
• Cochrane Central Register of Controlled Trials (CENTRAL) Issue 3 (from inception to 
December 1, 2018) 
• Bibliographies of eligible trials 
Search terms used for MEDLINE and Cochrane library 
MEDLINE: 
1. 1.(apn* or OSA* or SAHS or hypopn*).af. 
2. 2.(randomized controlled trial or controlled clinical trial).pt. or randomized.ab,ti. or 
placebo.ab,ti. ortrial.ti. or clinical trials as topic.sh. or randomly.ab,ti. 
3. 3.(*CPAP or positive airway pressure).af 
4. 1 and 2 and 3 
Cochrane Library: 
1. Apn* or OSA* or SAHS or hypopn* 
2. randomized or placebo or randomly or trial 
3. *CPAP or positive airway pressure 
4. 1 and 2 and 3 
Key: af = all fields, pt = publication type, ab = abstract, ti = title, sh = MeSH subject heading, OSA = 
obstructive sleep apnoea, SAHS = sleep apnoea/hypopnoea syndrome, CPAP = continuous positive 
airway pressure.  
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Statistical methods 
We combined data from the current study and the historical trials with a Bayesian analysis. We 
followed the idea of Baeten et al.3, but modified it in two major ways. First, we applied the 
bayesmeta R package for Bayesian random-effects meta-analysis4 instead of using MCMC 
sampling. Second, we considered both the control arm and the CPAP arm individually to 
compute priors based on historical data. We then calculated posterior probability of superiority 
of therapeutic CPAP versus sham CPAP. In addition, we quantified the probability of 
improvement in each of the treatment arms separately. Since Hoyos5 did not report standard 
deviations for change from baseline, we estimated these from pooled standard deviations for 
the treatment estimates. Data were analyzed with R (R Core Team (2018), R version 3.4.4 
(2018-03-15)). 
Data from four trials were included for ESS5-8, while only two provided historical data for BP5,6. 
Standard errors for the Hoyos trial5 were estimated from the confidence intervals reported for 
the treatment estimates, otherwise data were used as reported. In the current study data, we 
observed a difference in ESS between the treatment arms of about 3 (mean sham CPAP 2.2, 
therapeutic CPAP -0.9), while in the historical data, there was a mean difference about about 1 
(sham -0.8, CPAP -2.1). Small differences in blood pressure were also observed in the current 
study data (SBP: mean sham -0.3, CPAP -2.9; DBP: sham 2.1, CPAP -0.5), and in the historical 
data (SBP: sham 1.3, CPAP -0.01; DBP: sham -0.1, CPAP -0.7). The posterior mean [variance] 
ESS for the CPAP arm was -1.1 [0.17], and for the sham CPAP arm 0.06 [0.15]. The posterior 
mean systolic (diastolic) BP for the CPAP arm was -0.5 [0.92] (-0.7 [0.45]), and for the sham 
CPAP arm 1.2 [0.62] (0.1 [0.44]). Sampling from the posterior distributions, and computing the 
differences between the treatment arms, we obtained a median difference in delta ESS of 0.825 
(sham - CPAP, positive favors CPAP) (95% Credible Interval -0.41 to 2.05). The posterior 
probability of superiority of therapeutic CPAP vs sham CPAP was 90.4% with a Monte Carlo 
error of 0.0009. Similarly for systolic (diastolic) BP, the median difference in change was 1.6 
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[-0.8 to 4.0] (0.8 [-1.0 to 2.7]). The posterior probability of superiority of therapeutic CPAP vs 
sham CPAP for systolic (diastolic) BP was 90.2% (80.3%) with a MC error of 0.0009 (0.0013). 
Based on the posterior distributions, we also calculated the probability for each treatment arm 
that the mean difference was less than 0 (that is, that the outcome at follow-up was less than at 
baseline). With sham CPAP, the probability of a lower ESS score was only 44%, while with 
real CPAP, the probability was 99%. For systolic (diastolic) BP, the probability of a lower BP 
was 7% (44%) with sham, and 68% (86%) with real CPAP.  
We amended the approach of Baeten et al.3 for the two following reasons: 1) when applying 
bayesmeta, we do not need to consider burn-in or convergence diagnostics as bayesmeta is a 
numerical approach to Bayesian analysis, and 2) we use historical knowledge not only in the 
control group, but also in the treatment group. Baeten et al.3 planned the trial to include the 
historical data, while we performed a post-hoc analysis of a conventionally planned study. The 
choice of the half-normal heterogeneity prior with scale 0.5 was suggested by Friede et al.6 
They also provided satisfactory robustness analysis for this choice of prior. In our study 
however, we provided a robustness check, by computing the results with and without the Hoyos 
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ESS data BP data 
Hoyos et al. 20125 Parallel 3.0 3.6 65/52 34/28 31/24 Yes Yes 
McEvoy et al. 20168 Parallel 44.4 3.3 2409/2324 1221/1166 1188/1158 Yes Yes 
Redline et al. 19989 Parallel 2.0 3.1 111 59 52 Yes No 
Weaver et al. 201210 Parallel 2.0 4±2 281/223 141/113 140/110 Yes Yes 
 
 
* depending on the outcome (ESS data / BP data) 
 













Active smokers 6 (23.1%) 4 (15.4%) 
Ex-smokers 10 (43.5%) 11 (52.4%) 
Smoking start, age 24.1 ± 12.6 18.1 ± 4.4 
Smoking stop, age 42.8 ± 16.2 40.9 ± 10.9 
Pack years of smoking 16.6 ± 19.5 15.8 ± 14.9 
More than one alcoholic standard drink per day 16 (61.5%) 18 (69.2%) 
Obesity 17 (65.4%) 20 (76.9%) 
Arterial hypertension 17 (65.4%) 18 (69.2%) 
Dyslipidemia 9 (34.6%) 11 (42.3%) 
Diabetes 22 (84.6%) 22 (84.6%) 
Metabolic syndome 2 (7.7%) 3 (11.5%) 
Cerebrovascular event 3 (11.5%) 2 (7.7%) 
Atrial fibrillation 3 (11.5%) 4 (15.4%) 
Coronary artery disease 4 (15.4%) 2 (7.7%) 
Heart failure 1 (3.8%) 0 (0.0%) 
Aneurysm 2 (7.7%) 1 (3.8%) 
Chronic obstructive pulmonary disease 2 (7.7%) 1 (3.8%) 
Asthma 2 (7.7%) 2 (7.7%) 
Cancer (for more details see Table 7) 4 (15.4%) 2 (7.7%) 
Depression (for more details see Table 8) 2 (7.7%) 3 (11.5%) 
Schizophrenia (for more details see Table 8) 1 (3.8%) 0 (0%) 
Dementia (for more details see Table 9) 0 (0%) 1 (3.8%) 
Narcolepsy (treated) 0 (0%) 1 (3.8%) 
Miscellaneous 
Shift workers (for more details see Table 10) 1 (3.8%) 1 (3.8%) 
Data are n (%), or mean (SD) as appropriate. 
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Beta blocker 7 (26.9%) 5 (19.2%) 
Alpha blocker 1 (3.8%) 1 (3.8%) 
Angiotensin-converting-enzyme inhibitor 6 (23.1%) 4 (16.0%) 
Calcium channel blocker 2 (7.7%) 10 (38.5%) 
Angiotensin II receptor blocker 5 (19.2%) 6 (23.1%) 
Aldosteroneantagonist 0 (0.0%) 1 (3.8%) 
Diuretics 4 (16.0%) 6 (23.1%) 
Statins 7 (26.9%) 10 (38.5%) 
Insulin 2 (7.7%) 2 (7.7%) 
Oral antitiabetics 5 (19.2%) 4 (15.4%) 
Oral anticoagulation 4 (15.4%) 4 (15.4%) 
Aspirin 6 (23.1%) 6 (23.1%) 
Sodium oxybate 0 (0%) 0 (0%) 
Data are n (%) 
 










Systolic blood pressure, mmHg 133.2 ± 16.2 130.2 ± 13.0 0.477 
Diastolic blood pressure, mmHg 81.5 ± 7.4 81.7 ± 9.4 0.941 
Heart rate, bpm 72.6 ± 9.1 71.9 ± 11.5 0.827 
Noon 
Systolic blood pressure, mmHg 130.2 ± 12.1 130.8 ± 12.5 0.850 
Diastolic blood pressure, mmHg 79.8 ± 7.6 81.0 ± 8.2 0.592 
Heart rate, bpm 75.4 ± 9.1 75.5 ± 11.8 0.974 
Evening 
Systolic blood pressure, mmHg 134.6 ± 15.0 132.0 ± 16.1  0.709 
Diastolic blood pressure, mmHg 79.2 ± 8.3 80.1 ± 8.1 0.687 
Heart rate, bpm 78.3 ± 10.9 76.6 ± 9.5 0.550 
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Table 5. Suboptimal CPAP-adherence profiles of all study participants. 
Profile n (%) Examples 
Lifestyle 28 (49%) 
Shift workers with unregular sleep cycles, falling asleep while watching 
TV, decision to use CPAP only “on demand (… when symptomatic)”; 
“seasonal”; or “… at the beginning of the night”, social restrictions (bed-
partner, children, etc.), frequent traveling (to places without electricity) 
Comorbidities 25 (44%) 
Sleep-related neurological disorders (e.g. narcolepsy), cognitive 
disabilities (incl. dementia, depression, claustrophobia, etc.), airway-
related diseases (e.g. chronic sinusitis, chronic cough), nocturia, 
craniofacial abnormalities (operations etc.), gastroesophageal reflux 
disease, substance abuse (alcohol, drugs, etc.), schizophrenia, 
untreatable cancer, etc. 
Technical 4 (7%) 
Mask-related issues (leakages), suboptimal pressure settings, skin 
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Table 6. Recruitment details on average CPAP adherence by center. Ultimately, 
1,035 patients from nine Swiss sleep laboratory centers were recruited by the 
investigators at the study site in Zurich. 
Recruiting site Subjects screened Average CPAP adherence 
Kantonsspital Aarau 294 2.7 ± 1.4 
Kantonsspital Glarus 37 2.8 ± 1.1 
Kantonsspital Graubünden 131 2.8 ± 1.2 
Spital Horgen 16 2.9 ± 1.7 
Spital Männedorf 10 2.8 ± 1.6 
Kantonsspital Schaffhausen 8 3.6 ± 1.3 
Stadtspital Triemli 151 3.2 ± 1.2 
Universitätsspital Zürich* 268 3.2 ± 1.4 
Zürcher RehaZentrum Wald 120 2.9 ± 1.3 
 Sum: 1035 Average all centers: 3.0 ± 1.4 
 
* study site 
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Stage Treatment Follow up? 
Involvement 










carcinoma of the 
bladder 
May 2012 pT1 G3 
Transurethral resection (May 
2012) and epirubicin in May 
2012. 
Confirmed complete 




diagnosed in 2010 
treated with SNRI. 
5 Breast cancer 1993 
pT2 pN0 (0/3) M0 L1 
Pn0 R0 G2 HR+ Herz2- 
Ki67 20% 
Mastectomy 1993, 
chemotherapy (unclear) 1993, 
radiotherapy (unclear) 1993 
and hormonal therapy 
(Tamoxifen) since 1993 
Confirmed complete 
remission in November 
2014. 




1993 Stage I Inguinal orchiectomy 
Confirmed complete 
remission in 2010. 
No. No. No. 
27 Breast cancer July 2011 
pT1c(m) pN2a(5/15) G3 
/ ER 100% / PR 100% / 






2012 and hormonal therapy 
(Tamoxifen) since 2012 
Confirmed complete 
remission in December 
2015. 
No. Tamoxifen. No. 
32 Prostate cancer January 2017 T1 No M0 Transurethral resection 2017 
No follow-up due to recent 
diagnosis 
No. No. No. 
43 Breast cancer 
November 
1996 








diagnosed in 2009 
treated with SSRI. 
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Table 8. Additional information on the subgroup population with depression (10%, n=5) 
and schizophrenia (2%, n=1). 
 
Case Diagnosis Date of first diagnosis Treatment 
Use of 
hypnotics 
1 Depression unclear SSRI No 
2 Depression 2011 SNRI, psychotherapy No 
3 Depression 2009 SSRI No 
4 Depression 2005 SSRI, psychotherapy No 
12 Depression 2010 NDRI, psychotherapy No 





NDRI, Norepinephrine-dopamine reuptake inhibitor 
SSRI, Selective serotonin reuptake inhibitor 
SNRI, Serotonin–norepinephrine reuptake inhibitor 
 
Table 9. Additional information on the subgroup population with dementia (2%, n=1). 
 








Gingko leaves No 
 
Table 10. Additional information on the subgroup population of shift workers (4%, n=2). 
 






Since >10 years 
Permanent night shifts  
(1 AM to 9 AM) 
No 
52 Nurse For >10 years 
Alternating day and night shifts 
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Table 11. Additional information on the subgroup population (29%, n=15) with central 
nervous system (CNS) medications. 
Case Substance Dosage Administration Indication Changes* 
1 Escitalopram 10 mg 1x daily, oral Depression No 
2 Duloxetine 60 mg 1x daily, oral Depression No 
3 Escitalopram 10 mg 1x daily, oral Depression No 
3 Valproate 300 mg 1x daily, oral Epilepsy No 
4 Escitalopram 20 mg 1x daily, oral Depression No 




6 Cetirizine 10 mg 1x daily, oral Rhinitis No 
10 Quetiapine 25 mg 1x daily, oral Bipolar disorder No 
12 Trazodone 25 mg 1x daily, oral Insomnia No 
19 Levetiracetam 100 mg 2x daily, oral Epilepsy 
Dose increase 
to 3x daily at V4 
19 Fentanyl 2 mg 1x daily, dermal Pain No 
19 Trazodone 25 mg 1x daily, oral Insomnia No 




29 Bupropion 150 mg 1x daily, oral Depression No 
31 Oxycodon 10 mg 2x daily, oral Pain No 
33 Venlafaxine 150 mg 1x daily, oral Anxiety disorder No 




46 Amitriptyline 25 mg 2x daily, oral Migraine No 
46 Pregabalin 300 mg 1x daily, oral Pain No 
46 Lorazepam 1 mg 
1x daily, oral 
(on demand) 
Insomnia No 
46 Pramipexole 0.125 mg 1x daily, oral Parkinson No 
47 Trazodone 150 mg 




* Changes during the trial (V1 to V4) as noted on CRF 
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